International Clinical Trial: A Real-world Study of Patients With Hidradenitis Suppurativa and High Cardiovascular Risk or Established Coronary Plaque Treated With Secukinumab

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07454889) titled 'A Real-world Study of Patients With Hidradenitis Suppurativa and High Cardiovascular Risk or Established Coronary Plaque Treated With Secukinumab' on March 3.

Study Type: Observational

Primary Sponsor: Novartis Pharmaceuticals

Condition: Hidradenitis Suppurativa

Recruitment Status: Not recruiting

Date of First Enrollment: March 31, 2026

Target Sample Size: 34

To know more, visit https://clinicaltrials.gov/study/NCT07454889

Published by HT Digital Content Services with permission from Health Daily Digest....